Skip to main content
Erschienen in: Annals of Hematology 3/2015

01.03.2015 | Original Article

Trends in incidence and medical resource utilisation in patients with chronic lymphocytic leukaemia: insights from the UK Clinical Practice Research Datalink (CPRD)

verfasst von: A. M. Pfeil, P. Imfeld, R. Pettengell, S. S. Jick, T. D. Szucs, Christoph R. Meier, M. Schwenkglenks

Erschienen in: Annals of Hematology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in European adults. We aimed to evaluate time trends in CLL incidence and medical resource utilisation of CLL patients in the UK. We conducted a retrospective, observational cohort analysis using the UK Clinical Practice Research Datalink (CPRD) comprising mainly primary care data. We included adult patients with newly diagnosed CLL between January 2000 and June 2012. Descriptive and trend analyses of CLL incidence and medical resource utilisation were performed. A total of 2576 patients with CLL met the eligibility criteria. At diagnosis, the majority of patients (71.7 %) were above 65 years of age. The European age-standardised CLL incidence rate in the CPRD was 6.2/100,000 (95 % confidence interval [CI] 6.0, 6.5/100,000) person-years. There was no statistically significant increase over time. The CLL patients had on average 74.6 general practitioner visits during a median follow-up of 3.3 years. Between 2000 and 2012, the average number of recorded hospitalisations and referrals per year corrected for duration of follow-up significantly (p < 0.001) increased by 8.1 % (95 % CI 6.8 %, 9.3 %) and 16.4 % (95 % CI 15.4 %, 17.3 %), respectively. Referrals and hospitalisations in the second year compared to the first year following the CLL diagnosis significantly decreased. CLL incidence rates in the CPRD were stable over the period from 2000 to 2012. Medical resource utilisation in UK primary care was well documented, but further research is needed to describe secondary and tertiary care medical resource utilisation e.g. chemotherapy administration, which is inadequately captured in the CPRD.
Literatur
7.
Zurück zum Zitat Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grunhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jager U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Buhler A, Winkler D, Zenz T, Bottcher S, Ritgen M, Mendila M, Kneba M, Dohner H, Stilgenbauer S (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376(9747):1164–1174. doi:10.1016/S0140-6736(10)61381-5 PubMedCrossRef Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grunhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jager U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Buhler A, Winkler D, Zenz T, Bottcher S, Ritgen M, Mendila M, Kneba M, Dohner H, Stilgenbauer S (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376(9747):1164–1174. doi:10.​1016/​S0140-6736(10)61381-5 PubMedCrossRef
8.
Zurück zum Zitat Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Dohner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370(12):1101–1110. doi:10.1056/NEJMoa1313984 PubMedCrossRef Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Dohner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370(12):1101–1110. doi:10.​1056/​NEJMoa1313984 PubMedCrossRef
12.
Zurück zum Zitat Alexandropoulou K, van Vlymen J, Reid F, Poullis A, Kang JY (2013) Temporal trends of Barrett’s oesophagus and gastro-oesophageal reflux and related oesophageal cancer over a 10-year period in England and Wales and associated proton pump inhibitor and H2RA prescriptions: a GPRD study. Eur J Gastroenterol Hepatol 25(1):15–21. doi:10.1097/MEG.0b013e3283595086 PubMedCrossRef Alexandropoulou K, van Vlymen J, Reid F, Poullis A, Kang JY (2013) Temporal trends of Barrett’s oesophagus and gastro-oesophageal reflux and related oesophageal cancer over a 10-year period in England and Wales and associated proton pump inhibitor and H2RA prescriptions: a GPRD study. Eur J Gastroenterol Hepatol 25(1):15–21. doi:10.​1097/​MEG.​0b013e3283595086​ PubMedCrossRef
13.
14.
Zurück zum Zitat Jordan KP, Hayward RA, Blagojevic-Bucknall M, Croft P (2013) Incidence of prostate, breast, lung and colorectal cancer following new consultation for musculoskeletal pain: a cohort study among UK primary care patients. Int J Cancer 133(3):713–720. doi:10.1002/ijc.28055 PubMedCentralPubMedCrossRef Jordan KP, Hayward RA, Blagojevic-Bucknall M, Croft P (2013) Incidence of prostate, breast, lung and colorectal cancer following new consultation for musculoskeletal pain: a cohort study among UK primary care patients. Int J Cancer 133(3):713–720. doi:10.​1002/​ijc.​28055 PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR, Schlienger RG, Black C, Jick H (2003) Validity of the general practice research database. Pharmacotherapy 23(5):686–689PubMedCrossRef Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR, Schlienger RG, Black C, Jick H (2003) Validity of the general practice research database. Pharmacotherapy 23(5):686–689PubMedCrossRef
16.
Zurück zum Zitat Eurostat (2013) Revision of the European standard population—report of Eurostat’s task force. Methodologies & working papers, vol 2013 edition. doi:10.2785/11470 Eurostat (2013) Revision of the European standard population—report of Eurostat’s task force. Methodologies & working papers, vol 2013 edition. doi:10.​2785/​11470
17.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40(5):373–383PubMedCrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40(5):373–383PubMedCrossRef
18.
Zurück zum Zitat Al-Hashimi MM, Wang X (2013) Comparing the cancer in Ninawa during three periods (1980–1990, 1991–2000, 2001–2010) using Poisson regression. J Res Med Sci 18(12):1026–1039PubMedCentralPubMed Al-Hashimi MM, Wang X (2013) Comparing the cancer in Ninawa during three periods (1980–1990, 1991–2000, 2001–2010) using Poisson regression. J Res Med Sci 18(12):1026–1039PubMedCentralPubMed
19.
Zurück zum Zitat Cox DR (1972) Regression models and life-tables. J R Stat Soc Ser B Methodol 34(2):187–220 Cox DR (1972) Regression models and life-tables. J R Stat Soc Ser B Methodol 34(2):187–220
20.
Zurück zum Zitat Panovska A, Doubek M, Brychtova Y, Mayer J (2010) Chronic lymphocytic leukemia and focusing on epidemiology and management in everyday hematologic practice: recent data from the Czech Leukemia Study Group for Life (CELL). Clin Lymphoma Myeloma Leuk 10(4):297–300. doi:10.3816/CLML.2010.n.061 PubMedCrossRef Panovska A, Doubek M, Brychtova Y, Mayer J (2010) Chronic lymphocytic leukemia and focusing on epidemiology and management in everyday hematologic practice: recent data from the Czech Leukemia Study Group for Life (CELL). Clin Lymphoma Myeloma Leuk 10(4):297–300. doi:10.​3816/​CLML.​2010.​n.​061 PubMedCrossRef
21.
Zurück zum Zitat van den Broek EC, Kater AP, van de Schans SA, Karim-Kos HE, Janssen-Heijnen ML, Peters WG, Nooijen PT, Coebergh JW, Posthuma EF (2012) Chronic lymphocytic leukaemia in the Netherlands: trends in incidence, treatment and survival, 1989–2008. Eur J Cancer 48(6):889–895. doi:10.1016/j.ejca.2011.06.053 PubMedCrossRef van den Broek EC, Kater AP, van de Schans SA, Karim-Kos HE, Janssen-Heijnen ML, Peters WG, Nooijen PT, Coebergh JW, Posthuma EF (2012) Chronic lymphocytic leukaemia in the Netherlands: trends in incidence, treatment and survival, 1989–2008. Eur J Cancer 48(6):889–895. doi:10.​1016/​j.​ejca.​2011.​06.​053 PubMedCrossRef
22.
Zurück zum Zitat Cancer Research U (2012) CancerStats—incidence 2009—UK Cancer Research U (2012) CancerStats—incidence 2009—UK
23.
Zurück zum Zitat Boggon R, van Staa TP, Chapman M, Gallagher AM, Hammad TA, Richards MA (2013) Cancer recording and mortality in the General Practice Research Database and linked cancer registries. Pharmacoepidemiol Drug Saf 22(2):168–175. doi:10.1002/pds.3374 PubMedCrossRef Boggon R, van Staa TP, Chapman M, Gallagher AM, Hammad TA, Richards MA (2013) Cancer recording and mortality in the General Practice Research Database and linked cancer registries. Pharmacoepidemiol Drug Saf 22(2):168–175. doi:10.​1002/​pds.​3374 PubMedCrossRef
24.
Zurück zum Zitat Coebergh JW, Janssen-Heijnen ML, Post PN, Razenberg PP (1999) Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993–1996. J Clin Epidemiol 52(12):1131–1136PubMedCrossRef Coebergh JW, Janssen-Heijnen ML, Post PN, Razenberg PP (1999) Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993–1996. J Clin Epidemiol 52(12):1131–1136PubMedCrossRef
25.
Zurück zum Zitat Linn BS, Linn MW, Gurel L (1968) Cumulative illness rating scale. J Am Geriatr Soc 16(5):622–626PubMed Linn BS, Linn MW, Gurel L (1968) Cumulative illness rating scale. J Am Geriatr Soc 16(5):622–626PubMed
26.
Zurück zum Zitat Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, Mulsant B, Reynolds CF 3rd (1992) Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 41(3):237–248PubMedCrossRef Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, Mulsant B, Reynolds CF 3rd (1992) Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 41(3):237–248PubMedCrossRef
30.
Zurück zum Zitat Santosh J, Crampton P (2009) Gender differences in general practice utilisation in New Zealand. J Prim Health Care 1(4):261–269PubMed Santosh J, Crampton P (2009) Gender differences in general practice utilisation in New Zealand. J Prim Health Care 1(4):261–269PubMed
Metadaten
Titel
Trends in incidence and medical resource utilisation in patients with chronic lymphocytic leukaemia: insights from the UK Clinical Practice Research Datalink (CPRD)
verfasst von
A. M. Pfeil
P. Imfeld
R. Pettengell
S. S. Jick
T. D. Szucs
Christoph R. Meier
M. Schwenkglenks
Publikationsdatum
01.03.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 3/2015
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-014-2217-7

Weitere Artikel der Ausgabe 3/2015

Annals of Hematology 3/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.